☆ 4.2 Meeting Abstract

One Year Remission with Allogeneic Stem Cell Transplantation After Achieving Complete Response by Polatuzumab Vedotin for the Treatment of Refractory Diffuse Large B-Cell Lymphoma

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)

Add to Collection

Journal

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume 20, Issue -, Pages S261-S261

Publisher

CIG MEDIA GROUP, LP

Keywords

polatuzumab vedotin; relapsed/refractory NHL; combined chemotherapy; aggressive B-cell lymphoma; allogeneic stem cell transplant; ABCL

Categories

Oncology Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.